# Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)

Study · id `cardio:ct-nct04004793` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04004793](<https://clinicaltrials.gov/study/NCT04004793>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04004793

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 328 participants.

## Technical summary

Registry record NCT04004793. Randomized; triple masking; primary purpose treatment. Start 2020-06-12 (actual); primary completion 2023-01-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 328 participants (enrolled count; ClinicalTrials.gov record NCT04004793, source copy `cardio:ctgov-nct04004793-2024-07-24`, retrieved 2026-10-26)
- Started: 2020-06-12 (actual) (ClinicalTrials.gov record NCT04004793, source copy `cardio:ctgov-nct04004793-2024-07-24`, retrieved 2026-10-26)
- Primary completion: 2023-01-31 (actual) (ClinicalTrials.gov record NCT04004793, source copy `cardio:ctgov-nct04004793-2024-07-24`, retrieved 2026-10-26)
- Completion: 2023-01-31 (actual) (ClinicalTrials.gov record NCT04004793, source copy `cardio:ctgov-nct04004793-2024-07-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04004793, source copy `cardio:ctgov-nct04004793-2024-07-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04004793-2024-07-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)
- Acronym: READ
- Condition: Type 2 Diabetes
- Intervention (Behavioral): Intensive lifestyle intervention
- Intervention (Drug): Dapagliflozin 10 MG Oral Tablet
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: Shanghai Zhongshan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Shanghai Zhongshan Hospital (`cardio:org-shanghai-zhongshan-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial (`cardio:pubmed-39843169`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e512ac4c1f850121889dbd4d5531af46af5b6c7c8a22d5358320c750d95d7b12
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
